IDEAYA Biosciences (IDYA) has moved into focus after two clinical updates, a new collaboration with Roche on IDE892 plus RG6505 in MTAP deleted pancreatic cancer, and Phase 2/3 darovasertib data in metastatic uveal melanoma.

Despite the recent collaboration with Roche and positive darovasertib data at ASCO, IDEAYA Biosciences’ share price has come under pressure in recent months, with a 90 day share price return down 19.4%, although the 1 year total shareholder return of 30.2% still reflects earlier momentum.

If you are looking beyond IDEAYA and want more ideas in healthcare related technology, this could be a good moment to scan 39 healthcare AI stocks

With IDEAYA Biosciences now trading at US$28.29 and screening on some models as intrinsically discounted, the question for investors is simple: is this weakness an opening, or is the market already pricing in future growth?

Preferred Price-to-Sales of 11x: Is it justified?

On simple multiples, IDEAYA Biosciences trades on a P/S of 11x, which screens as expensive next to several reference points despite the recent share price pullback.

The P/S ratio compares the company’s market value with its revenue. This is a common yardstick for early stage or loss making biotechs where earnings are not yet positive. For IDEAYA Biosciences, this means investors are currently paying 11 times trailing revenue for exposure to its pipeline and partnerships.

That 11x sits above the estimated fair P/S ratio of 2.6x, a level our models suggest the market could trend toward if sentiment or revenue expectations shift. At the same time, the stock trades below the peer group average P/S of 19.4x and slightly above the broader US biotech average of 10.1x. This places it in an interesting middle ground between sector enthusiasm and what the fair ratio model implies.

Result: Price-to-Sales of 11x (OVERVALUED).

However, there are clear risks as well, including ongoing net losses of US$140.059 million and reliance on successful trial outcomes and partner collaborations to support the pipeline.

Another View: DCF Points the Other Way

While the P/S ratio presents IDEAYA Biosciences as expensive, the SWS DCF model tells a different story. At $28.29, the stock is described as trading 83% below an estimated future cash flow value of $166.61, which frames the current price as heavily discounted instead of stretched.

This gap between the revenue based multiple and the DCF output raises a simple question for you as an investor: which set of assumptions feels more realistic for a loss making biotech with high forecast revenue growth?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out IDEAYA Biosciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals across valuation models, does the story look more exciting or more cautious to you? Consider reviewing both the upside and downside factors, and weigh the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

Do not stop with one stock when you can line up a watchlist of strong candidates that fit different goals, risk levels, and income needs.

• Target potential mispricing by scanning 49 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect their financial strength.
• Prioritise resilience by reviewing the 61 resilient stocks with low risk scores that score well on balance sheet strength and lower overall risk factors.
• Strengthen your income focus by checking the 9 dividend fortresses that combine higher yields with an emphasis on staying power.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.